A recent study suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional diet and exercise programs.
Published data in a leading health publication shows that while obese people often shed substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying these treatments must be informed of the potential of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery suggests a return to starting weight within about a year and a half.
Comparing Treatments
The research, which looked at 37 of studies involving thousands of participants, contrasted the effects of these new drugs with conventional dieting.
The team note that people who lose weight through lifestyle changes alone usually have a less rapid creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Nutrition scientists believe the mechanism of the drugs accounts for the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Condition?
Medical guidelines recommend the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, considering the significant potential of relapse, the therapy is often life-long.
This view is reinforced by pharmaceutical companies, who say that the findings "underscore the long-term character of obesity," akin to managing conditions like hypertension.
Patient Testimonies
People who have discontinued the medication explain a powerful return of cravings.
"It felt as if a trigger that goes on and I was suddenly ravenous," said an individual.
The struggle is compounded if users have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is higher among women than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers caution that while these medications are potent tools for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing behavioural management.
